Global measles cases surge as 30 million children miss vaccines, UN health agency warns

The WHO warns global measles outbreaks are accelerating after pandemic-related disruption left as many as 30 million children under-protected, with roughly 11 million infections and an estimated 95,000 deaths last year—mostly children under five and concentrated in Africa and the Eastern Mediterranean. In 2024, 59 countries experienced large or disruptive outbreaks (nearly three times 2021 levels); global coverage was 84% for the first dose but only 76% for the second, and WHO is urging stronger surveillance, faster outbreak response and renewed political commitment while the “Big Catch-Up” campaign has reached more than 11 million children through 2025.

Analysis

Market structure: The immediate beneficiaries are vaccine manufacturers, diagnostics and cold‑chain/distribution providers because WHO/Gavi “catch‑up” campaigns imply a multi‑year demand surge: ~30m under‑protected children implies tens of millions of additional MMR doses ordered through 2025–26, concentrating incremental revenues among a few global suppliers. Losers are fragile EM sovereigns (higher near‑term health spending) and thin‑margin local producers who can’t scale; pricing power will shift modestly to large-cap suppliers because supply is concentrated and ramp times are months, not weeks.

Risk assessment: Tail risks include a production shutdown at a major supplier (Serum Institute/large OEM) or a donor funding shortfall (Gavi/G7 commitments failing) — both would spike spot prices and procurement scramble within 30–90 days. Immediate market moves will be news‑driven; expect order flow and margin relief for suppliers over 3–12 months; structural demand (routine immunisation strengthening) is a 1–3 year thematic. Hidden dependency: procurement is donor‑funded — corporate upside is gated to public commitments and cold‑chain logistics capacity.

Trade implications: Favor selective longs in vaccine OEMs and diagnostics/distribution names with visible global footprints and supply capacity, using 6–12 month horizons; hedge EM sovereign exposure and crowding. Options: prefer directional call spreads on core beneficiaries to cap premium outlay while capturing seasonally concentrated procurement windows (Q3–Q4 2025). Rebalance away from EM local‑currency debt and small-cap EM healthcare suppliers.

Contrarian angles: Consensus underestimates how concentrated dose manufacturing creates pricing leverage and order visibility for a handful of suppliers — equity markets may be underpricing a 5–15% revenue tailwind for leaders over 12 months. Historical parallel: polio catch‑ups produced 12–24 month procurement spikes that benefited suppliers more than NGOs; unintended consequence: political backlash on mandates could create episodic volatility and reputational risk for large manufacturers.

Key Decisions for Investors

• Establish a 1–2% long position in MRK (Merck & Co.) sized to portfolio risk tolerance to capture incremental MMR procurement through 2025–26; target 12–18% price upside over 6–12 months, set tactical stop‑loss at 8% and reassess after major donor commitments (Gavi/G7) within 60 days.
• Add a 0.5–1% long position in TMO (Thermo Fisher) to play diagnostics/surveillance demand and reagent volume growth; use 9‑month 1:2 call spread (buy 9‑month ATM call, sell 9‑month higher strike) to limit premium with a trigger to add on weakness >10%.
• Implement a relative‑value pair: long MRK (0.75%) vs short PFE (0.75%) for 6–12 months to express vaccine exposure vs general pharma; rebalance if MRK/PFE spread narrows >6 percentage points or after quarterly supply updates.
• Reduce EM local‑currency sovereign exposure by 1–2% of portfolio (trim EMB/ILF holdings) and reallocate into developed‑market healthcare names; rationale: higher fiscal pressure in fragile states and donor‑gated demand creates asymmetric risk in EM credit over next 12 months.